Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H9NO3 |
Molecular Weight | 131.1299 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCC(=O)CCC(O)=O
InChI
InChIKey=ZGXJTSGNIOSYLO-UHFFFAOYSA-N
InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
Molecular Formula | C5H9NO3 |
Molecular Weight | 131.1299 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Aminolevulinic Acid is the first compound in the porphyrin synthesis pathway. The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical
pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rather a
metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is
normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by
intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the
accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus. Marketed under the brand name LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator, it is indicated for the treatment of minimally to moderately
thick actinic keratoses (Grade 1 or 2, see table 2 for definition) of the face or scalp. Aminolevulinic acid is also being studied in the treatment of other conditions and types of cancer. An orally-administered in vivo diagnostic agent, Aminolevulinic acid, is used in photodynamic diagnosis
(PDD) whose aim is to help doctors visualize the tumor tissue during surgical resection of malignant glioma, it is
already sold in over 20 European countries including Germany and the U.K. According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12493610 | https://www.ncbi.nlm.nih.gov/pubmed/9792218
Curator's Comment: There is low permeability of the undisrupted BBB in humans
Originator
Sources: http://www.mdpi.com/1420-3049/16/5/4140
Curator's Comment: The first report on excessive protoporphyrin accumulation and high photosensitivity after exogenous administration of ALA in humans was presented by Berlin et al. in 1956
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LEVULAN KERASTICK Approved UseThe LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue
Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately
thick actinic keratoses (Grade 1 or 2, see table 2 for definition) of the face or scalp. Launch Date9.4452482E11 |
|||
Diagnostic | Gliolan Approved UseGliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant
glioma (WHO grade III and IV). Launch Date1.16760956E12 |
|||
Primary | ALA Approved UseCondylomata Acuminata Launch Date1.17141117E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8239.1 μg/L |
20 mg/kg bw single, oral dose: 20 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1862.6 μg/L |
2 mg/kg bw single, oral dose: 2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
274.7 μg/L |
0.2 mg/kg bw single, oral dose: 0.2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.44 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11961050/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.65 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11961050/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27143.5 μg × h/L |
20 mg/kg bw single, oral dose: 20 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2901.3 μg × h/L |
2 mg/kg bw single, oral dose: 2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
424.2 μg × h/L |
0.2 mg/kg bw single, oral dose: 0.2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
13.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11961050/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11961050/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.94 h |
20 mg/kg bw single, oral dose: 20 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.84 h |
2 mg/kg bw single, oral dose: 2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.75 h |
0.2 mg/kg bw single, oral dose: 0.2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
50.1 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11961050/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
44.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11961050/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
88% |
20 mg/kg bw single, oral dose: 20 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
88% |
2 mg/kg bw single, oral dose: 2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
88% |
0.2 mg/kg bw single, oral dose: 0.2 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
AMINOLEVULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg/kg single, oral Recommended Dose: 20 mg/kg Route: oral Route: single Dose: 20 mg/kg Sources: |
unhealthy, 70.5 years (range: 53–84 years) n = 61 Health Status: unhealthy Condition: primary or recurrent non-muscle-invasive bladder cancer Age Group: 70.5 years (range: 53–84 years) Sex: M+F Population Size: 61 Sources: |
Other AEs: Alanine aminotransferase increase, Hypotension... Other AEs: Alanine aminotransferase increase (grade 3, 6.6%) Sources: Hypotension (grade 3, 1.6%) Urticaria (grade 3, 1.6%) |
10 % 1 times / day multiple, topical Recommended Dose: 10 %, 1 times / day Route: topical Route: multiple Dose: 10 %, 1 times / day Sources: Page: p. 44 |
unhealthy n = 384 Health Status: unhealthy Sex: M+F Population Size: 384 Sources: Page: p. 44 |
Disc. AE: Application site burning, Application site pain... AEs leading to discontinuation/dose reduction: Application site burning (1 patient) Sources: Page: p. 44Application site pain (1 patient) |
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
healthy n = 6 |
|
100 mg single, oral |
healthy n = 6 |
|
1328 mg single, intravesical Dose: 1328 mg Route: intravesical Route: single Dose: 1328 mg Sources: |
unhealthy n = 8 Health Status: unhealthy Condition: recurrent bladder cancer Population Size: 8 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | grade 3, 1.6% | 20 mg/kg single, oral Recommended Dose: 20 mg/kg Route: oral Route: single Dose: 20 mg/kg Sources: |
unhealthy, 70.5 years (range: 53–84 years) n = 61 Health Status: unhealthy Condition: primary or recurrent non-muscle-invasive bladder cancer Age Group: 70.5 years (range: 53–84 years) Sex: M+F Population Size: 61 Sources: |
Urticaria | grade 3, 1.6% | 20 mg/kg single, oral Recommended Dose: 20 mg/kg Route: oral Route: single Dose: 20 mg/kg Sources: |
unhealthy, 70.5 years (range: 53–84 years) n = 61 Health Status: unhealthy Condition: primary or recurrent non-muscle-invasive bladder cancer Age Group: 70.5 years (range: 53–84 years) Sex: M+F Population Size: 61 Sources: |
Alanine aminotransferase increase | grade 3, 6.6% | 20 mg/kg single, oral Recommended Dose: 20 mg/kg Route: oral Route: single Dose: 20 mg/kg Sources: |
unhealthy, 70.5 years (range: 53–84 years) n = 61 Health Status: unhealthy Condition: primary or recurrent non-muscle-invasive bladder cancer Age Group: 70.5 years (range: 53–84 years) Sex: M+F Population Size: 61 Sources: |
Application site burning | 1 patient Disc. AE |
10 % 1 times / day multiple, topical Recommended Dose: 10 %, 1 times / day Route: topical Route: multiple Dose: 10 %, 1 times / day Sources: Page: p. 44 |
unhealthy n = 384 Health Status: unhealthy Sex: M+F Population Size: 384 Sources: Page: p. 44 |
Application site pain | 1 patient Disc. AE |
10 % 1 times / day multiple, topical Recommended Dose: 10 %, 1 times / day Route: topical Route: multiple Dose: 10 %, 1 times / day Sources: Page: p. 44 |
unhealthy n = 384 Health Status: unhealthy Sex: M+F Population Size: 384 Sources: Page: p. 44 |
PubMed
Title | Date | PubMed |
---|---|---|
Photodynamically induced effects in colon carcinoma cells (WiDr) by endogenous photosensitizers generated by incubation with 5-aminolaevulinic acid. | 1999 Apr |
|
Topical drug delivery in humans with a single photomechanical wave. | 1999 Nov |
|
Renal toxicity of the carcinogen delta-aminolevulinic acid: antioxidant effects of melatonin. | 2000 Dec 8 |
|
The morphological changes in rat bladder after photodynamic therapy with 5-aminolaevulinic acid-induced protoporphyrin IX. | 2000 Jul |
|
An affordable, portable fluorescence imaging device for skin lesion detection using a dual wavelength approach for image contrast enhancement and aminolaevulinic acid-induced protoporphyrin IX. Part I. Design, spectral and spatial characteristics. | 2001 |
|
Multiple biosynthetic pathways for vitamin B12: variations on a central theme. | 2001 |
|
Topical photodynamic therapy at low fluence rates--theory and practice. | 2001 Apr |
|
Evaluation of different photosensitizers for use in photochemical gene transfection. | 2001 Apr |
|
Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid. | 2001 Apr |
|
Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. | 2001 Apr |
|
Peritoneal endometriosis detection. | 2001 Apr |
|
Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. | 2001 Apr |
|
Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I. | 2001 Aug |
|
Correlation between lead exposure indicators and sister chromatid exchange (SCE) frequencies in lymphocytes from inorganic lead exposed workers. | 2001 Aug |
|
Recognition and transport characteristics of nonpeptidic compounds by basolateral peptide transporter in Caco-2 cells. | 2001 Aug |
|
Fluorescence spectroscopy of normal mouse skin exposed to 5-aminolaevulinic acid and red light. | 2001 Aug 15 |
|
Photodynamic therapy with topical delta-aminolaevulinic acid for the treatment of plantar warts. | 2001 Aug 15 |
|
Melatonin prevents delta-aminolevulinic acid-induced oxidative DNA damage in the presence of Fe2+. | 2001 Feb |
|
Systemic vs local administration of delta-aminolevulinic acid for laparoscopic fluorescence diagnosis of malignant intra-abdominal tumors. Experimental study. | 2001 Feb |
|
Imaging of the lower urinary tract in adults. | 2001 Feb |
|
Photodynamic diagnosis with 5-aminolevulinic acid in the treatment of secondary urethral tumors: first in vitro and in vivo results. | 2001 Feb |
|
Suppression of the induction of long-term depression by carbon monoxide in rat cerebellar slices. | 2001 Feb |
|
Treatment of multiple scalp basal cell carcinomas by photodynamic therapy. | 2001 Jan |
|
[Photodynamic therapy of nasal basal cell carcinoma]. | 2001 Jan |
|
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. | 2001 Jan 1 |
|
Tissue distribution and penetration of 5-ALA induced fluorescence in an amelanotic melanoma after topical application. | 2001 Jan-Feb |
|
Photodynamic therapy with 5-aminolevulinic acid induces apoptosis and caspase activation in malignant T cells. | 2001 Jan-Feb |
|
Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. | 2001 Jul |
|
Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. | 2001 Jul 20 |
|
Mechanistic basis for suicide inactivation of porphobilinogen synthase by 4,7-dioxosebacic acid, an inhibitor that shows dramatic species selectivity. | 2001 Jul 27 |
|
Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer. | 2001 Jun 1 |
|
Evidence for direct interaction between enzyme I(Ntr) and aspartokinase to regulate bacterial oligopeptide transport. | 2001 Jun 15 |
|
Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. | 2001 Mar |
|
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. | 2001 Mar |
|
Expression of coproporphyrinogen oxidase and synthesis of hemoglobin in human erythroleukemia K562 cells. | 2001 Mar |
|
Photodynamic therapy for Bowen's disease (squamous cell carcinoma in situ) of the digit. | 2001 May |
|
Fluorescence detection of cervical intraepithelial neoplasia for photodynamic therapy with the topical agents 5-aminolevulinic acid and benzoporphyrin-derivative monoacid ring. | 2001 May |
|
Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia. | 2001 May 25 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Can also be used orally for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV): the recommended dose is 20 mg 5-ALA HCl per kilogram body weight. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000744/WC500021790.pdf
LEVULAN KERASTICK for Topical Solution 20% (aminolevulinic acid HCl) is intended for direct application to individual
lesions diagnosed as actinic keratoses and not to perilesional skin. This product is not intended for
application by patients or unqualified medical personnel. Application should involve either scalp or
face lesions, but not both simultaneously. The recommended treatment frequency is: one application of
the LEVULAN KERASTICK Topical Solution and one dose of illumination per treatment site per 8
week treatment session. Each individual LEVULAN KERASTICK should be used for only one
patient. Photodynamic therapy for actinic keratoses with LEVULAN KERASTICK for Topical
Solution is a two stage process involving a) application of the product to the target lesions with
LEVULAN KERASTICK Topical Solution, followed 14 to 18 hours later by b) illumination with blue
light using the BLU-U Blue Light Photodynamic Therapy Illuminator. The second visit, for
illumination, must take place in the 14-18 hour window following application.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27764515
Curator's Comment: Glioma cells, seeded at the bottom of 96-well plates and incubated with ALA (10 ug/ml) for 6 h, were exposed to the sinusoidal US pulses with a resonance frequency of 1 MHz, 1000 µs duration, 0.4 duty-cycle, and average acoustic power varying from 2 W to 6 W. Ultrasound waves were generated by a flat circular piezoelectric transducer with a diameter of 25 mm. Cell viability was determined by MTT assay.
Aminolevulinic acid (10 ug/ml) mediated sonosensitization of rat RG2 glioma cells in vitro. ALA-mediated SDT evokes cytotoxic effects of low intensity US on rat RG2 glioma cells in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:13:01 UTC 2023
by
admin
on
Wed Jul 05 23:13:01 UTC 2023
|
Record UNII |
88755TAZ87
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175846
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
387312
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
710519
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
WHO-ATC |
L01XD04
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
CFR |
21 CFR 862.1060
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
NCI_THESAURUS |
C1420
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
WHO-VATC |
QL01XD04
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
FDA ORPHAN DRUG |
811521
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
NDF-RT |
N0000171207
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1811
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
88755TAZ87
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
17549
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
137
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
D000622
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
AMINOLEVULINIC ACID
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
4784
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
88755TAZ87
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
DTXSID8048490
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
100000089317
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
C234
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
M1713
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB12853MIG
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
106-60-5
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
DB00855
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
166
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
683
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY | |||
|
155002
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
ALTERNATIVE | |||
|
203-414-1
Created by
admin on Wed Jul 05 23:13:01 UTC 2023 , Edited by admin on Wed Jul 05 23:13:01 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|